CRUK Cambridge Research Institute, Cambridge, UK.
EMBO J. 2011 May 20;30(13):2719-33. doi: 10.1038/emboj.2011.158.
The androgen receptor (AR) is a key regulator of prostate growth and the principal drug target for the treatment of prostate cancer. Previous studies have mapped AR targets and identified some candidates which may contribute to cancer progression, but did not characterize AR biology in an integrated manner. In this study, we took an interdisciplinary approach, integrating detailed genomic studies with metabolomic profiling and identify an anabolic transcriptional network involving AR as the core regulator. Restricting flux through anabolic pathways is an attractive approach to deprive tumours of the building blocks needed to sustain tumour growth. Therefore, we searched for targets of the AR that may contribute to these anabolic processes and could be amenable to therapeutic intervention by virtue of differential expression in prostate tumours. This highlighted calcium/calmodulin-dependent protein kinase kinase 2, which we show is overexpressed in prostate cancer and regulates cancer cell growth via its unexpected role as a hormone-dependent modulator of anabolic metabolism. In conclusion, it is possible to progress from transcriptional studies to a promising therapeutic target by taking an unbiased interdisciplinary approach.
雄激素受体(AR)是前列腺生长的关键调节剂,也是治疗前列腺癌的主要药物靶点。先前的研究已经绘制了 AR 靶点,并确定了一些可能有助于癌症进展的候选靶点,但没有以综合的方式描述 AR 生物学。在这项研究中,我们采取了跨学科的方法,将详细的基因组研究与代谢组学分析相结合,确定了一个涉及 AR 作为核心调节剂的合成代谢转录网络。限制合成代谢途径的通量是剥夺肿瘤维持肿瘤生长所需的构建块的一种有吸引力的方法。因此,我们寻找可能有助于这些合成代谢过程的 AR 靶点,并通过在前列腺肿瘤中的差异表达使其成为有治疗干预潜力的靶点。这突出了钙/钙调蛋白依赖性蛋白激酶激酶 2(CaMKKK2),我们发现它在前列腺癌中过表达,并通过其作为激素依赖性合成代谢调节剂的意外作用调节癌细胞生长。总之,通过采取公正的跨学科方法,从转录研究进展到有前途的治疗靶点是可能的。